AB Science said it received a notice of allowance from the European Patent Office for a patent covering the use of the experimental oral therapy masitinib to treat sickle cell disease (SCD). The ...
Note: This column describes the author’s own experiences with various medications, including nonsteroidal anti-inflammatory drugs and oral opioids. Not everyone will have the same response to ...
As a health professional and sickle cell patient, I’m constantly driven to create awareness about the disease. My motivation transcends professional duty; it’s a personal quest to make a difference.